Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2020

Open Access 01-12-2020 | Helicobacter Pylori | Debate

The diffuse-type gastric cancer epidemiology enigma

Authors: Paulo Pimentel Assumpção, Williams Fernandes Barra, Geraldo Ishak, Luiz Gonzaga Vaz Coelho, Felipe José Fernandez Coimbra, Helano Carioca Freitas, Emmanuel Dias-Neto, M. Constanza Camargo, Moyses Szklo

Published in: BMC Gastroenterology | Issue 1/2020

Login to get access

Abstract

Background

Intestinal and diffuse gastric adenocarcinomas differ in clinical, epidemiological and molecular features. However, most of the concepts related to the intestinal-type are translated to gastric adenocarcinoma in general; thus, the peculiarities of the diffuse-type are underappreciated.

Results

Besides its growing importance, there are many gaps about the diffuse-type carcinogenesis and, as a result, its epidemiologic and pathogenetic features remain poorly understood.

Conclusions

Alternative hypotheses to explain these features are discussed, including the role of the gastric microbiota, medical therapies, and modifications in the stomach’s microenvironment.
Literature
1.
Bray F, Ferlay J, Soerjomataran I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
2.
Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26–8.PubMed
3.
Waldum HL, Fossmark R. Types of gastric carcinomas. Int J Mol Sci. 2018;19(12):4109.CrossRef
4.
Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomark Prev. 2009 Jul;18(7):1945–52.CrossRef
5.
Wachtel MS, Zhang Y, Chiriva-Internati M, Frezza EE. Different regression equations relate age to the incidence of Lauren types 1 and 2 stomach cancer in the SEER database: these equations are unaffected by sex or race. BMC Cancer. 2006;6:65.CrossRef
6.
Lee E, Liu L, Zhang J, et al. Stomach Cancer disparity among Korean Americans by tumor characteristics: comparison with non-Hispanic whites, Japanese Americans, south Koreans, and Japanese. Cancer Epidemiol Biomark Prev. 2017 Apr;26(4):587–96.CrossRef
7.
Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to helicobacter pylori. Int J Cancer. 2015;136(2):487–90.CrossRef
8.
Petrelli F, Berenato R, Turati L, et al. Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. J Gastrointest Oncol. 2017;8(1):148–63.CrossRef
9.
Bonequi P, Meneses-González F, Correa P, et al. Risk factors for gastric cancer in Latin America: a meta-analysis. Cancer Causes Control. 2013;24(2):217–31.CrossRef
10.
Wang Q, Chen Y, Wang X, et al. Consumption of fruit, but not vegetables, may reduce risk of gastric cancer: results from a meta-analysis of cohort studies. Eur J Cancer. 2014;50(8):1498–509.CrossRef
11.
Crowe SE. Helicobacter pylori infection. N Engl J Med. 2019;380(12):1158–65.CrossRef
12.
Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of Metachronous gastric Cancer. N Engl J Med. 2018;378(12):1085–95.CrossRef
13.
Choi IJ, Kim CG, Lee JY, Kim YI, Kook MC, Park B, Joo J. Family history of gastric Cancer and helicobacter pylori treatment. N Engl J Med. 2020;382(5):427–36.CrossRef
14.
de Assumpção PP, Araújo TMT, de Assumpção PB, Barra WF, et al. Suicide journey of H. pylori through gastric carcinogenesis: the role of non-H. pylori microbiome and potential consequences for clinical practice. Eur J Clin Microbiol Infect Dis. 2019;38(9):1591–7.CrossRef
15.
Take S, Mizuno M, Ishiki K, et al. Risk of gastric cancer in the second decade of follow-up after helicobacter pylori eradication. J Gastroenterol. 2020;55(3):281–8.CrossRef
16.
Inoue M. Changing epidemiology of helicobacter pylori in Japan. Gastric Cancer. 2017;20:3–7.CrossRef
17.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.CrossRef
18.
Kim SK, Kim HJ, Park JL, Heo H, Kim SY, Lee SI, Song KS, Kim WH, Kim YS. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer. Gastric Cancer. 2020;23(3):473–82.CrossRef
19.
Oue N, Sentani K, Sakamoto N, Uraoka N, Yasui W. Molecular carcinogenesis of gastric cancer: Lauren classification, mucin phenotype expression, and câncer stem cells. Int J Clin Oncol. 2019;24(7):771–8.CrossRef
20.
Binato R, Santos EC, Boroni M, Demachki S, Assumpção P, Abdelhay E. A common molecular signature of intestinal-type gastric carcinoma indicates processes related to gastric carcinogenesis. Oncotarget. 2017;9(7):7359–71.CrossRef
21.
Yan HHN, Siu HC, Law S, et al. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. Cell Stem Cell. 2018;23(6):882–97 e11.CrossRef
22.
Zhang C, Min L, Liu J, et al. Integrated analysis identified an intestinal-like and a diffuse-like gene sets that predict gastric cancer outcome. Tumor Biol. 2016;37(12):16317–35.CrossRef
23.
Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004;157:327–49.
24.
Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449–56.CrossRef
25.
Correa P, Houghton J. Carcinogenesis of helicobacter pylori. Gastroenterology. 2007;133(2):659–72.CrossRef
26.
Haastrup P, Paulsen MS, Zwisler JE, et al. Rapidly increasing prescribing of proton pump inhibitors in primary care despite interventions: a nationwide observational study. Eur J Gen Pract. 2014;20(4):290–3.CrossRef
27.
Wang LL, Yu XJ, Zhan SH, Jia SJ, Tian ZB, Dong QJ. Participation of microbiota in the development of gastric cancer. World J Gastroenterol. 2014;20(17):4948–52.CrossRef
28.
Imhann F, Vich Vila A, Bonder MJ, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8(4):351–8.CrossRef
29.
Saeki N, Saito A, Choi IJ, et al. A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology. 2011;140(3):892–902.CrossRef
30.
Sala N, Muñoz X, Travier N, et al. Prostate stem-cell antigen gene is associated with diffuse and intestinal gastric cancer in Caucasians: results from the EPIC-EURGAST study. Int J Cancer. 2012;130(10):2417–27.CrossRef
31.
Cao H, Wang B, Zhang Z, et al. Distribution trends of gastric polyps: an endoscopy database analysis of 24121 northern Chinese patients. J Gastroenterol Hepatol. 2012;27(7):1175–80.CrossRef
Metadata
Title
The diffuse-type gastric cancer epidemiology enigma
Authors
Paulo Pimentel Assumpção
Williams Fernandes Barra
Geraldo Ishak
Luiz Gonzaga Vaz Coelho
Felipe José Fernandez Coimbra
Helano Carioca Freitas
Emmanuel Dias-Neto
M. Constanza Camargo
Moyses Szklo
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2020
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-020-01354-4

Other articles of this Issue 1/2020

BMC Gastroenterology 1/2020 Go to the issue

Research article

HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients: a retrospective study of 250 cases

Case report

Leukocytoclastic vasculitis as a rare dermatologic manifestation of Crohn’s disease mimicking cellulitis: a case report

Research article

Optimization of impedance-measured reflux events in GORD utilizing acid exposure time

Research article

Non-alcoholic fatty liver disease among patients with sleep disorders: a Nationwide study of Taiwan

Case report

Eosinophilic peritonitis with colon cancer: a case report

Case report

Misdiagnosis of peripheral abscess caused by duodenal foreign body: a case report and literature review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits